Index

ACC/AHA Performance Measures, 109–110
acute coronary syndrome, 4
administrator, of HF programs, 76–77
Agency for Healthcare Research and
Quality, 73
aldosterone antagonists, 61, 124–126
American College of Cardiology (ACC), 2
American Heart Association (AHA), 2, 12
angiotensin-converting enzyme (ACE)
inhibitors, 13, 52–53, 62–63, 73, 84, 103,
121–123, 122–123
angiotensin receptor blockers (ARBs), 6, 61,
63, 102
Audicor TS system, 146
B natriuretic peptide measurements, 17, 55,
143
diagnostic testing, 102
financial pro forma/5-year projections,
29–30
guiding principles, 25–27
market survey of HF services in area,
27–28
mission statement, 22–25
opportunities/threats, 30
organization structure of HF program,
28–29
review of HF care in practice, 27
underpromise/overdeliver strategy, 66

β–blocker therapy, 6, 12–13, 52, 63–64, 73,
84, 87, 126–128
billing codes
for ACE inhibitor/ARB
hydralazine-nitrate therapy, 63
for β–blocker therapy, 64
for consultations, 61, 62
for special visits, 65
for spironolactone therapy, 65
Bio-Z and B-natriuretic peptide testing, 56,
68, 103
Bisoprolol titration, 128
biventricular pacing systems, 56
change
resistance to, 11
classes, of patients
NYHA Class I, 14, 41, 47, 83
NYHA Class II, 14, 47, 60, 61
NYHA Class III, 60, 61, 82, 83
Cardiodynamics Bio-Z system, 56, 145, 146
carvedilol titration, 127
cardiac resynchronization therapy (CRT),
56, 144, 146–147
case managers, of HF patients
determining need for, 83
patient advocacy by, 82–83
qualities of, 83
supplementation by nurse practitioners,
84
change
Index

NYHA Class IIIA, 47
NYHA Class IIIB, 14, 41, 47
NYHA Class IV, 60, 61, 83
clinic staff, of HF programs, 84
clinical director, of HF programs
characteristics of, 76
patient consultations with physician, 87
searching for, 75
codes
for billing
ACE inhibitor/ARB
hydralazine-nitrate therapy, 63
β–blocker therapy, 64
special visits, 65
spironolactone therapy, 65
for evaluation and management, 52, 62, 67, 68
ICD-9
for projection of program revenues, 48–49
for services generated by research programs, 50
for supervision of care, 53
for telemannagement, 53
communities
avoidance of program replication, 27
choice of HF programs, 5–6
HF programs area survey for business plan, 27–28
Community Health Continuity Clinic (CHCC), group visits program, 54, 65–66, 112–113, 133
compliance issues, of patients, 114–116
consultations
billing codes for, 61, 62
drop-in group medical appointments, 54, 66
in hallway, 13
initial consult, 102–103
nurse practitioners with physicians, 84
for nutritional therapy, 65
preconsultation visit/procedures, 55–56, 62, 93
day-to-day operations, of HF clinic
baseline assessments, 93–107
follow-up visits, 109–120
telemanagement algorithms, 133–140
treatment protocols, 121–132
defibrillators (implanted), 56, 144
device therapy, 144–147
diagnostic/therapeutic testing/procedures, of HF care, 54–57, 102. See also baseline assessments; nutritional assessment; questionnaires
ACE inhibitors, 13, 52–53, 62–63, 84, 103, 121–122
aldosterone antagonists, 61, 124–126
angiotensin receptor blockers (ARBs), 6, 61, 63, 102
B natriuretic peptide measurements, 17, 55
β–blocker therapy, 6, 12–13, 52, 63–64
Bio-Z and B-natriuretic peptide testing, 56, 68, 103
biventricular pacing systems, 56
cardiac resynchronization therapy (CRT), 56, 144, 146–147
Cardiodynamics Bio-Z system, 56, 145, 146
clinical goals of, 113–114
defibrillators (implanted), 56, 144
echocardiogram procedures, 17
external counterpulsation (ECP) therapy, 56, 143–144
HF symptom assessment, 128–129
hydralazine-nitrate therapy, 63, 123
Inovise Audicor system, 56
Medtronic OptiVol system, 56
metolazone, 65
neurohormonal therapy, 1, 61
noninvasive hemodynamic testing, 68
nutritional therapy, 65
preconsult visit, 55
6-minute walk test, 68
spironolactone therapy, 54, 65
dietary services, of HF programs, 84–85
Digoxin protocol, 129–130
diuretic therapy protocol, 130–131
drop-in group medical appointment (DIGMA), 54, 66, 112–113, 133
E/M (evaluation and management)
codes/services, 52, 62, 66–67, 68
echocardiogram procedures, 17
education, of patients about HF, 1–2, 35
Educational Questionnaire, 111–112
essential elements, 111
HFSA guidelines, 2, 110–111
for hospitalization-rehospitalization
avoidance, 34
when to call guidelines, 114
Epworth Sleepiness Scale, 55, 100
erectile dysfunction questionnaire. See
Sexual Health Inventory for Men
Questionnaire
European Society of Cardiology, 2
examination rooms, determination of
number needed, 88
external counterpulsation (ECP) therapy, 56,
143–144
failure, of HF programs, 11
financial pro forma, for business plan, 29–30
front office support, for HF programs, 77
group visits
at Community Health Continuity Clinic,
54, 65–66, 112–113, 133
drop-in group medical appointment, 54
guidelines for, 112–113
vs. “incident to” strategy, 553
growth-limiting resource (GLR), to HF
programs, 4–5, 16–17
Guidant Latitude system, 56
guidelines, for patients, 2
guiding principles, in business plan, 25–27
hallway consultations, 13
health satisfaction questionnaire (SF26), 55
heart failure clinic, physical facility, 87–90
examination room determination, 88
infusion suite, 88–89
support space, 89–90
telemanagement area, 89
heart failure (HF) programs
avoidance of program replication, 27
clinic staff of, 64
community choices, 5–6
day-to-day operations
baseline assessments, 93–107
follow-up visits, 109–120
telemanagement algorithms, 133–140
treatment protocols, 121–132
diagnostic/therapeutic procedures, 54–57
dietary services of, 84–85
formula for success
commitment to benchmarks, 17–18
growth-limiting resource model of
care, 16–17
heart failure patient availability, 9–11
independent/competent staff, 15–16
physician as champion, 11–15
GLR of, 16–17
hospital-based, 22
individual decision, 1, 3–5
limitation considerations, 5
physicians as driving force, 3, 11–14
reasons for failure, 11
resource intensiveness of, 10–11
therapeutic goals, 113–114
heart failure (HF) programs, creation of
assigning credit for revenues, 49–50
in current health care environment,
45–47
diagnostic/therapeutic procedures, 54–57
estimating sources of revenue, 48–49
group visits strategy, 53–54
“incident to” billing examples, 50–53
program costs, 47–48
reasons for, 45
scope of program decisions, 56–57
heart failure (HF) programs, management
administrator, 76–77
clinical director, 75–76
front office support, 77
oversight bodies, 77–78
physician champion/medical director,
73–74
heart failure (HF) programs, pro forma,
59–70
assessent of patient population, 59–60
diagnostic testing, 67–68
“incident to” revenues, 62–66
physician revenue assessment, 60–62
program expenses, 66–67
relative value units (RVU) approach,
68–69
second year evolution, 69–70
therapeutic procedures, 68
Heart Failure Society of America, 2, 110–111
hemodynamic testing, noninvasive, 68
HIPPA waiver, for group visits, 112
hospital-based HF programs, 22, 34
hospitalization-rehospitalization cycle, 34
hydralazine-nitrate therapy, 63, 123
implanted defibrillators, 56, 144
“incident to” billing practices, 50–53
confusion created by, 51
“incident to” revenues, 62–66
for leveraging of physician resources, 66
outpatient design setting, 51
provided by physician’s employees, 51
titration of ACE inhibitor therapy
example, 52–53
infusion suite therapy, 88–89, 141–143
initial consultation, 102–103
Inovise Audicor system, 56
Joint Commission on Accreditation of
Healthcare Organizations, 73
Kansas City Cardiomyopathy
Questionnaire, 55, 95–98
laboratory assessments
B natriuretic peptide measurements, 17, 55, 143
calcium/magnesium levels, 104
chest X-rays, 104
HIV testing, 104
H&P, 104
metabolic profile, 104
TSH levels, 104
urinalysis, 104
lifestyle changes, 116–120. See also
nutritional assessment; questionnaires
management, of HF programs. See heart
failure (HF) programs, management
market survey, for business plan, 27–28
medical history, at initial consult, 102
Medicare patient cohort, 10
Medtronic OptiVol system, 56, 144–145
Mended Hearts patient organization, 12
metolazone, 65
Minnesota Living with Heart Failure
Questionnaire, 55, 94–95
mission statement, for business plan, 22–25
avoidance of platitudes, 23
description of offered programs, 24–25
examples/types of, 23–24
statement of commitments, 25
models, of disease management
ACC/AHA performance measures, 33
deciding on, 33–36, 43
limitations of current model, 34
multidisciplinary team model, 39–41
nurse case manager model, 41–43
patient contacts with
nonphysicians/physicians, 3–4
physician extender model, 37–39
physicians as driving force, 3
multidisciplinary HF team model, 39–41
neurohormonal therapy, 1, 61
noninvasive hemodynamic testing, 68, 103
nurse case manager HF model, 41–43
nurse practitioners, 11, 54
patient consultations with physician, 84, 87
supplementation of case managers, 84
nutritional assessment
Dietary Recall Diary, 118–119
Food Frequency Checklist, 119
Nutritional Assessment Form, 117–118
NYHA functional classes, of patients, 14, 94
organizational structure, of HF programs,
28–29
outcomes, layering of, 105–106
intermediate-term, 106
long-term, 106
short-term, 106
oversight bodies, for HF programs, 77–78
patients. See also classes, of patients
attachment to staff, 81, 82
compliance issues, 114–116
contacts with nonphysicians/physicians,
3–4
difficulties from, 1–2
education of, 1–2, 35, 111–112
HFSA guidelines for, 2, 110–111
HR program flow, 10–11
increasing compliance of, 114–116
medication choices, 1, 6
systems for tracking, 56
telephonic encounter algorithm, 136–138
when to call guidelines, 114
physical (H&P) examination, at initial consult, 102
physicians
as champion/driving force, 3, 9, 11–15, 29, 36, 37, 43, 73–74
consultations w/nurse practitioners, 84
as “growth-limiting resource,” 4–5
and multidisciplinary team model, 39–41
and nurse case manager model, 41–43
physician-driven HF clinic model, 36–37
and physician extender HF model, 37–39
revenue determination, 60–62
spironolactone therapy, 54, 65
preconsultation visit/procedures, 55–56, 62, 93
Prospective Evaluation of Enhanced External Counterpulsation in Congestive Heart Failure (PEECH) trial, 56
protocols. See treatment protocols

questionnaires
ACC/AHA Performance Measures, 109–110
Berlin Questionnaire, 98–99
Dietary Recall Diary, 118–119
Educational Questionnaire, 111–112
Epworth Sleepiness Scale, 55, 100
Food Frequency Checklist, 119
health satisfaction questionnaire (SF26), 55
Kansas City Cardiomyopathy Questionnaire, 55, 95–98
Minnesota Living with Heart Failure Questionnaire, 55, 94–95
Nutritional Assessment Form, 117–118
for quality-of-life, 62
Sexual Health Inventory for Men Questionnaire, 55, 100–102
telephone administration of, 139
refractory coronary heart disease, 56
risk factors, for non-compliance, 116
self-care, 13–14
Sexual Health Inventory for Men Questionnaire, 55, 100–102
shared vision, for HP programs, 21
6-minute walk test, 68
sleep disturbances questionnaire, 55
sleep issues/questionnaires, 55, 98–100
staff, of HP programs
as heart of programs, 15–16
implementation of protocols, 87
supervision of care codes (99374-99379), 53
support space, 89–90
telemanagement
algorithms of, 133–140
area size requirements, 89
codes (99371-99373), 53
contact/encounter variables, 135–138
guidelines for management, 134
initial level contacts principles, 135
intensity determination, 140
of medications, 139–140
outsourcing of, 138–139
patient encounter algorithm, 136–138
testing. See diagnostic/therapeutic testing/procedures, of HF care
therapeutic procedures. See
treatment protocols

ACE inhibitors, 13, 52–53, 62–63, 73, 84, 103, 121–122, 121–123
advanced therapies
device therapy, 144–147
electronic care coordination, 143–144
infusion suite, 141–143
aldosterone antagonists, 61, 124–126
ARBs, 122–123
β-blocker therapy, 6, 12–13, 52, 63–64, 84, 87, 126–128
Bisoprolol titration, 128
carvedilol titration, 127
Toprol XL titration, 127–128
Digoxin protocol, 129–130
diuretic therapy, 130–131
HF symptom assessment, 128–129
Index

- hydralazine-nitrate therapy, 63, 123–124
- implementation of, 87
- telemanagement of, 139

- underdiagnosis/undertreatment, of HF, 14
- underpromise/overdeliver strategy, in business development, 66